Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0519-0130 formulation comparison in overweight/obesity
NCT06642571Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2024
- Primary completion
- May 2025
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised trial of NNC0519-0130 in obesity (4 arms), sponsored by Novo Nordisk. Primary endpoint: Area Under the Plasma Concentration-Time Curve at Steady State at 7 days. Started Oct 2024; status: completed.
02
Drugs
NNC0519-0130
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06642571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06642571.